dinaciclib
Small moleculeexperimental
Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications. — Wikipedia
Clinical trial activity
18 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
9
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00871663)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Prolymphocytic · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
- Cyclin-dependent kinase 5INHIBITOR
CDK5 inhibitor
- Cyclin-dependent kinase 1INHIBITOR
CDK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12- Mol. weight
- 396.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDinaciclib ↗
- ChEMBLCHEMBL2103840 ↗
Also known as
- dinaciclib
- dinaciclib
- dinaciclib
- dinaciclib
- dinaciclib
- mk-7965
- mk-7965
- mk-7965
- sch727965
- sch 727965
- sch 727965
- sch 727965
- sch-727965
- sch-727965
- sch-727965
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03484520 | Phase 1 | Jul 23, 2018 | AbbVie, Merck |
| NCT01676753 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | Merck, University of California, San Francisco |
| NCT02684617 | Phase 1 | Mar 29, 2016 | Merck |
| NCT01783171 | Phase 1 | Jan 1, 2013 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT01711528 | Phase 1 | Dec 19, 2012 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01650727 | Phase 1 | Oct 1, 2012 | Merck |
| NCT01624441 | Phase 1 | Aug 21, 2012 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT01580228 | Phase 3 | Aug 1, 2012 | Merck |
| NCT01515176 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2012 | National Cancer Institute (NCI), Ohio State University |
| NCT01434316 | Phase 1 | Nov 1, 2011 | Harvard University, National Cancer Institute (NCI) |
| NCT01026324 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Harvard University, National Cancer Institute (NCI) |
| NCT01096342 | Phase 2 | Jul 1, 2009 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00937937 | Phase 2 | Jul 1, 2009 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT00871546 | Phase 2 | Mar 1, 2009 | Merck |
| NCT00798213 | Phase 2 | Jan 1, 2009 | Merck |
| NCT00732810 | Phase 2 | Jul 1, 2008 | Merck |
| NCT00871910 | Phase 1 | Oct 1, 2006 | Merck |
| NCT00871663 | Phase 1 | Aug 1, 2006 | Merck |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 10 | 8 | 3 | 2006 |
| National Cancer Institute (NCI) | Government | 8 | 8 | 2 | 2009 |
| Harvard University | Academic/Hospital | 2 | 0 | 2 | 2009 |
| Mayo Clinic | Academic/Hospital | 2 | 0 | 2 | 2009 |
| AbbVie | For profit | 1 | 1 | 1 | 2018 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Southwest Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2012 |
10 organizations
Page 1 / 1